- Phase III prevention trial showed subcutaneous administration of investigational antibody cocktail casirivimab and imdevimab reduced risk of symptomatic COVID-19 infections by 81%
- New Roche data at 2021 AAN highlight impact and breadth of expanding neuroscience portfolio
- Roche launches Elecsys Anti-p53 immunoassay to aid diagnosis of various cancer types
- Roche launches Elecsys Epstein-Barr Virus (EBV) immunoassay panel to improve EBV infection staging
- Roche’s Evrysdi approved by European Commission as first and only at home treatment for spinal muscular atrophy
- Roche receives positive CHMP opinion for Tecentriq as a first-line monotherapy treatment for people with a type of metastatic non-small cell lung cancer
- Roche commences tender offer for all shares of GenMark Diagnostics, Inc. for $24.05 per share in cash
- Roche launches new high throughput configurations for cobas pro integrated solutions to increase testing efficiency
- New phase III data shows investigational antibody cocktail casirivimab and imdevimab reduced hospitalisation or death by 70% in non-hospitalised patients with COVID-19
- Roche provides update on tominersen programme in manifest Huntington’s disease
More ▼
Key statistics
52-week range
Markit short selling activity
Open | 0.00 |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | 247.60 |
Average volume | -- |
---|---|
Shares outstanding | -- |
Free float | -- |
P/E (TTM) | -- |
Market cap | -- |
EPS (TTM) | -- |
Annual div (ADY) | 8.24 EUR |
---|---|
Annual div yield (ADY) | -- |
Div ex-date | Mar 18 2021 |
Div pay-date | Mar 22 2021 |
Data delayed at least 15 minutes, as of Jun 28 2019 16:41 BST.
More ▼